Also known as: DMT fumarate
DMT fumarate refers to dimethyl fumarate delayed-release oral capsules, an FDA-approved treatment for relapsing forms of multiple sclerosis in adults. It is dosed twice daily and includes indication coverage for clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Initial U.S. approval was in 2013.
A phase 2 trial found that a single intravenous dose of dimethyltryptamine (DMT) alongside psychotherapy significantly reduced major depressive disorder symptoms, with effects lasting up to 6 months.
A phase IIa clinical trial found that a single intravenous dose of dimethyltryptamine (DMT) with psychological support rapidly reduced depressive symptoms in 34 adults with major depressive disorder, with improvements sustained for up to three months.
